Download PDF
Z Gastroenterol 2019; 57(06): 785-786
DOI: 10.1055/a-0902-6286
Mitteilungen
© Georg Thieme Verlag KG Stuttgart · New York

Allogene, mesenchymale Stammzellen zur Behandlung des akut-auf-chronischen Leberversagens – Initiierung der allo-APZ2-ACLF-II-01-Studie

Further Information

Publication History

Publication Date:
06 June 2019 (online)

Also available at
    Permissions and Reprints

Andreas Teufel1, Nils Tappenbeck2, Marco Berning3, Christian Lange5, Kathrin Dieter2, Ali Canbay5, Mark Andreas Kluth2, Matthias Ebert1

1 II. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim

2 RHEACELL GmbH & Co. KG, Heidelberg

3 Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden (TU Dresden), Dresden

4 Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Essen

5 Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie, Otto-von-Guericke-Universität, Magdeburg

 

  • Literatur

  • 1 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851
    CrossrefPubMedGoogle Scholar
  • 2 Moreau R, Jalan R, Gines P. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-1437, 1437 e1421-e1429
    CrossrefPubMedGoogle Scholar
  • 3 Jalan R, Saliba F, Pavesi M. et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61: 1038-1047
    CrossrefPubMedGoogle Scholar
  • 4 Hernaez R, Sola E, Moreau R. et al. Acute-on-chronic liver failure: an update. Gut 2017; 66: 541-553
    CrossrefPubMedGoogle Scholar
  • 5 Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol 2016; 13: 131-149
    CrossrefPubMedGoogle Scholar
  • 6 Bernal W, Jalan R, Quaglia A. et al. Acute-on-chronic liver failure. Lancet 2015; 386: 1576-1587
    CrossrefPubMedGoogle Scholar
  • 7 Casiraghi F, Remuzzi G, Abbate M. et al. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev 2013; 9: 65-79
    CrossrefPubMedGoogle Scholar
  • 8 Berardis S, Dwisthi Sattwika P, Najimi M. et al. Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects. World J Gastroenterol 2015; 21: 742-758
    CrossrefPubMedGoogle Scholar
  • 9 Gazdic M, Arsenijevic A, Markovic BS. et al. Mesenchymal Stem Cell-Dependent Modulation of Liver Diseases. Int J Biol Sci 2017; 13: 1109-1117
    CrossrefPubMedGoogle Scholar
  • 10 Meier RP, Muller YD, Morel P. et al. Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence?. Stem Cell Res 2013; 11: 1348-1364
    CrossrefPubMedGoogle Scholar
  • 11 Tappenbeck N, Schröder HM, Niebergall-Roth E. et al. In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials. Cytotherapy 2019; 21: 546-560
    CrossrefPubMedGoogle Scholar
  • 12 Vander Beken S, de Vries JC, Meier-Schiesser B. et al. Newly defined ATP-binding cassette subfamily B member 5 positive dermal mesenchymal stem cells promote healing of chronic iron-overload wounds via secretion of Interleukin-1 receptor antagonist. Stem Cells 2019; DOI: 10.1002/stem.3022. [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 13 Kim G, Eom YW, Baik SK. et al. Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis. J Korean Med Sci 2015; 30: 1405-1415
    CrossrefPubMedGoogle Scholar
  • 14 Lin BL, Chen JF, Qiu WH. et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology 2017; 66: 209-219
    CrossrefPubMedGoogle Scholar